Gsk Share Discussion Threads

[abdullla] 20/3/2020 08:56

Every thing is up apart from GSK is it the rising pound or the worst about divi

[abdullla] 19/3/2020 17:03

Thanks TM I think we both have a point,on the other hand IMO reinvesting the forthcoming dividend may not be a good idea,hopefully we get it intact,save it until all is clear, thanks again :-))

[tradermichael] 19/3/2020 16:48

abdullla: GSK have the adjuvant technology which is worth a lot of money in any vaccine that becomes developed (An adjuvant is an ingredient used in some vaccines that helps create a stronger immune response in people receiving the vaccine. ... Adjuvants help the body to produce an immune response strong enough to protect the person from the disease he or she is being vaccinated against.)

[abdullla] 19/3/2020 16:41

After my post below GSK spiked 18p,i am genius ?

[abdullla] 19/3/2020 16:22

It could cost GSK billions to fully develop a Coronavirus vaccine which they cant afford hence they have decided not to take this path but let the big boys with deep pockets burn the money instead.

[abdullla] 19/3/2020 15:27

But GSK has already announced the dividend & the payment timetable .

[quepassa] 19/3/2020 15:04

If front-runner Gilead Sciences do it..........rocket-ship

ALL IMO. DYOR.
QP

[zicopele] 19/3/2020 13:36

Dividend not safe.

How can it be safe with fall off in sales and recession everywhere

[alphorn] 19/3/2020 12:46

Roche on the case:

Roche has now announced the initiation of a Phase III clinical trial of Actemra/RoActemra (tocilizumab) in hospitalised patients with severe COVID-19 pneumonia.

The pharma giant says that it is working with the US Food & Drug Administration (FDA) to initiate the randomised, double-blind, placebo-controlled study, to evaluate the safety and efficacy of the drug in combo with standard of care.

This is the first global study of Actemra/RoActemra in this setting and is expected to begin enrolling as soon as possible in early April with a target of approximately 330 patients globally, including the US.

Roche has confirmed that primary and secondary endpoints include clinical status, mortality, mechanical ventilation and intensive care unit (ICU) variables.


Note: a PIII trial.

[watfordhornet] 19/3/2020 10:12

Why the drop?

[daveboy1] 19/3/2020 08:51

Share price not playing currently :(

[tradermichael] 19/3/2020 08:02

Wow:

GBP 1.0 = USD 1.15

Big boost to GSK, (also dividend safe for sure)

[watfordhornet] 18/3/2020 18:22

It has been. I know it is down but is my best performer - crazy I know but a 4.3% reduction today almost feels good compared to othersAgree with zicopele on sterling

[zicopele] 18/3/2020 16:40

Depreciation of Stg will provide some support.

Expecting fall in dividend.

[mister md] 18/3/2020 14:21

would have expected GSK to be a bit more resilient to the market sell off

[abdullla] 18/3/2020 13:08

Unlike India or Japan Big pharmas are not talking any chances which could backfire.

[abdullla] 18/3/2020 13:03

TM i think reading between the lines it answers my question,I hope the experts sort this mess out sooner than latter.

[abdullla] 18/3/2020 12:16

Some companies have cancelled their forthcoming dividend,is there any chance GSK could do the same ???

[tradermichael] 17/3/2020 16:50

Over 22 million GSK shares traded today

GBP 1.0 = USD 1.20, good for income

[alphorn] 17/3/2020 12:40

Der US-Pharmakonzern Pfizer arbeitet mit der Mainzer Biotech-Firma BioNtech SE an der Entwicklung eines Coronavirus-Impfstoffs. They collaborated from 2018.

[crossing_the_rubicon] 17/3/2020 12:29

Regeneron reported that tests for its "antibody-based" remedies for the coronavirus infection could be ready for the final round of clinical testing by the beginning of the summer, which could see a drug shipped by the end of the summer, according to CNBC's Meg Tirrell.

Pfizer, meanwhile, announced it would partner with a Swiss biotech company to produce a vaccine using a technology similar to Moderna.

Reporting from Beijing, CNBC's Eunice Yoon, reported that a Chinese trial for favipiravir, another antiviral designed to treat the virus, showed "promising" results.

[crossing_the_rubicon] 17/3/2020 11:24

A potential COVID-19 vaccine from Moderna (NASDAQ:MRNA) has moved into human testing, with the first participant receiving treatment on Monday. A total of 45 healthy adults will receive one of three dose levels (25, 100, 250 µg) of the candidate, called mRNA-1273, and will be followed for 12 months after receiving the second vaccination. The primary endpoint is safety, including reactogenicity (the expected adverse events such as excessive immunological responses and injection site reactions). The secondary endpoint is immunogenicity (the robustness of the immune response).

[tradermichael] 17/3/2020 08:18

GBP 1.00 = USD 1.22